Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Fadaki, Niloofar ^a   Cardona Huerta, Servando ^a,b   Martineau, Lea ^a   Thummala, Suresh ^a   Cheng, Shih Tsung ^a,c   Bunker, Steve R ^a   Garcia Kennedy, Richard ^a   Wang, Wei ^a   Minor, David ^a   Kashani Sabet, Mohammed ^b   Leong, Stanley P L ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VEMURAFENIB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; AXILLA; AXILLARY LYMPH NODE; CANCER STAGING; CANCER SURGERY; CASE REPORT; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; ELBOW; ENDOCARDITIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LOCAL EXCISION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; NECK; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84872137366     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007034     Document Type: Article

References (19)

1. McLoughlin JM, Zager JS, Sondak VK, et al. Treatment options for limited or symptomatic metastatic melanoma. Cancer control. J Mof fitt Cancer Center 2008;15:239-47.
2. Feun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma (stage IVA melanoma). Cancer 1982;50:1656-63.
3. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997;79:2345-53.
4. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004;16:155-60.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
6. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1:395-405.
7. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
8. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:1239-46.
9. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol/Oncol Clin North Am 2009;23:529-45, ix.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
11. Gibbs P, Anderson C, Pearlman N, et al. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 2002;94:470-6.
12. Lewis KD, Robinson WA, McCarter M, et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:3157-63.
13. Buzaid AC, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998;8:549-56.
14. Tarhini AA, Pahuja S, Kirkwood JM. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol 2011;104:386-90.
15. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res Off J Am Assoc Cancer Res 2011;17:6574-81.
16. Fletcher WS, Daniels DS, Sondak VK, et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol 1993;16:359-62.
17. Tarhini A, Edington H, Butterfield LH, et al. Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: immunogenicity and biomarker analysis. 2011 ASCO Annual Meeting. Chicago, IL, USA.
18. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
19. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901.